Martoni A, Pacciarini M A, Pannuti F
Drugs Exp Clin Res. 1985;11(2):127-31.
4-Demethoxydaunorubicin (4-DMDR) was administered orally at the dose of 15 mg/m2 daily for 3 consecutive days at three-weekly intervals to 28 patients with advanced pretreated breast cancer and 9 patients with disseminated pretreated melanoma. A partial remission was observed in 6 out of 20 evaluable breast cancer patients (30%) for a median duration of 6 months and in one out of 7 evaluable patients with melanoma (14%) for a duration of 3 months. Side-effects included leucopenia in 78% of patients (less than 1000 wbc/cmm in 8%), nausea in 32% and mild vomiting in 16%. The preliminary results of this ongoing study on 4-DMDR administered orally show that the regimen is well tolerated in the majority of patients and that it has antitumour activity in advanced breast cancer.
对28例晚期经预处理的乳腺癌患者和9例播散性经预处理的黑色素瘤患者，以15mg/m²的剂量口服4-去甲氧柔红霉素（4-DMDR），连续3天，每3周重复一次。20例可评估的乳腺癌患者中有6例（30%）出现部分缓解，中位缓解持续时间为6个月；7例可评估的黑色素瘤患者中有1例（14%）出现部分缓解，缓解持续时间为3个月。副作用包括78%的患者出现白细胞减少（8%的患者白细胞计数低于1000/mm³），32%的患者出现恶心，16%的患者出现轻度呕吐。这项正在进行的口服4-DMDR研究的初步结果表明，该方案在大多数患者中耐受性良好，并且对晚期乳腺癌具有抗肿瘤活性。
